Mission Wealth Management LP Reduces Stock Position in Humana Inc. (NYSE:HUM)

Mission Wealth Management LP cut its holdings in shares of Humana Inc. (NYSE:HUM) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,032 shares of the insurance provider’s stock after selling 48 shares during the quarter. Mission Wealth Management LP’s holdings in Humana were worth $262,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HUM. FPC Investment Advisory Inc. purchased a new stake in Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC purchased a new stake in Humana during the 4th quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new stake in Humana during the 3rd quarter worth approximately $31,000. Atwood & Palmer Inc. increased its holdings in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in Humana during the 4th quarter worth approximately $49,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.32% of the company’s stock.

Humana Trading Up 1.3 %

Shares of HUM stock opened at $265.59 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The stock has a fifty day moving average of $271.72 and a two-hundred day moving average of $284.78. The firm has a market capitalization of $32.04 billion, a PE ratio of 26.69, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HUM shares. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Twenty investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.